keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous immunotherapy

keyword
https://www.readbyqxmd.com/read/29146015/tablet-based-sublingual-immunotherapy-for-respiratory-allergy
#1
REVIEW
L Prieto
Allergic respiratory disease represents a significant and expanding health problem worldwide. The gold standard of therapeutic intervention is still grucocorticosteroids, although they are not effective in all patients and may cause side effects. Allergen Immunotherapy has been administrated as subcutaneous injections for treatment of allergic rhinoconjunctivitis and asthma and has been practiced for the past century. Sublingual immunotherapy (SLIT) tablets are now available for grass- or ragweed-induced rhinoconjunctivitis and will be available in Spain for house dust mite (HDM)-induced rhinoconjunctivitis and asthma in the next months...
November 13, 2017: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/29141287/-observation-of-systemic-adverse-reactions-by-specific-immunotherapy-and-analysis-of-risk-factors-in-allergic-rhinitis
#2
Y Shen, S L Hong, M Zhang, X Ke
Objective: To investigate the systemic adverse effects of specific subcutaneous immunotherapy (SCIT) in patients with allergic rhinitis (AR) and explore the possible risk factors. Methods: A retrospective study was conducted on AR patients who underwent SCIT from January 2014 to January 2017 in Department of Otorhinolaryngology, the First Affiliated Hospital of Chongqing Medical University. For patients with adverse reactions, the detailed medical history during treatment was reviewed. Results: A total of 1608 injections were performed on 102 patients, there were 12 cases / 21 times systemic adverse events, including systemic urticaria, angioedema and Grade Ⅰ systemic adverse reactions...
November 7, 2017: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
https://www.readbyqxmd.com/read/29130994/enhancement-of-anti-leukemia-immunity-by-leukemia-derived-exosomes-via-downregulation-of-tgf-%C3%AE-1-expression
#3
Fang Huang, Jiangbo Wan, Weiwei Hu, Siguo Hao
BACKGROUND/AIMS: Minimal residual leukemia cells (MRLs) are difficult to eradicate through traditional treatment and therefore remain to be a major threat to the long-term survival of leukemia patients. Tumor-derived exosomes (TEXs), which carry tumor associated antigens (TAA), may be a potential cell-free tumor vaccine for the specific eradication of MRLs. However, TEXs are intended to be less immunogenic due to exosomal TGF-β1. To further optimize the efficacy of TEX-based vaccines, we investigated whether exosomes from TGF-β1 silenced leukemia cells (LEXTGF-β1si) had an increased potential to induce a specific antitumor effect compared with non-modified exosomes...
November 9, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29130794/allergen-immunotherapy-for-birch-apple-syndrome-what-do-we-know
#4
Cristoforo Incorvaia, Erminia Ridolo, Marina Mauro, Marina Russello, Elide Pastorello
Apple allergy is common in patients allergic to birch pollen, and this is defined as 'birch-apple syndrome'. Allergens responsible for cross-reactivity belong to the pathogenesis-related-10 family, and high homology in the amino acid sequences of the major allergens Bet v 1 from birch and Mal d 1 from apple has been demonstrated. Here we review the literature on the treatment of birch-apple syndrome by allergen immunotherapy. The only allergen immunotherapy method available thus far is based on the administration of birch-pollen extracts, through the subcutaneous or sublingual route, to induce tolerance to Bet v1 and to the homologous allergen Mal d 1...
November 2017: Immunotherapy
https://www.readbyqxmd.com/read/29129888/-clinical-efficacy-of-sublingual-immunotherapy-in-the-third-treated-year-with-japanese-cedar-pollinosis-in-2017
#5
Atsushi Yuta, Yukiko Ogawa, Yusuke Suzuki, Hitomi Ogihara, Nobuo Ohta, Hideaki Kozaki, Takeshi Shimizu
It past 3 years in 2017 after the first purchase of the drug for sublingual immunotherapy (SLIT) for Japanese Cedar pollinosis (JCP). We reported the clinical efficacy of SLIT in the first and the second treated year. PURPOSE: The purpose of this study is to clear the clinical efficacy of SLIT in the third treated year by comparing with other therapies, such as subcutaneous immunotherapy (SCIT), or other pharmacotherapy. METHODS: We compared the clinical efficacy in 2017, of 112 SLIT in the third treated year with 38 SCIT, 364 primary pharmacotherapy that started therapies before pollen dispersal, 254 pharmacotherapy that started therapies after pollen disposal, or 333 non-treatment...
2017: Arerugī, [Allergy]
https://www.readbyqxmd.com/read/29128670/synchronous-immune-alterations-mirror-clinical-response-during-allergen-immunotherapy
#6
Amedee Renand, Mohamed H Shamji, Kristina M Harris, Tielin Qin, Erik Wambre, Guy W Scadding, Peter A Wurtzen, Stephen J Till, Alkis Togias, Gerald T Nepom, William W Kwok, Stephen R Durham
BACKGROUND: Three years treatment with either sublingual or subcutaneous allergen immunotherapy has been shown to be effective and to induce long-term tolerance. The GRASS(∗) trial demonstrated that two years treatment via either route was effective in suppressing the response to nasal allergen challenge, although was insufficient for inhibition one year after discontinuation. OBJECTIVE: To examine in the GRASS trial the time-course of immunologic changes during two years sublingual and subcutaneous immunotherapy and for one year after treatment discontinuation...
November 8, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29120699/tolerability-response-and-outcome-of-high-risk-neuroblastoma-patients-treated-with-long-term-infusion-of-anti-gd2-antibody-ch14-18-cho
#7
Ina Mueller, Karoline Ehlert, Stefanie Endres, Lena Pill, Nikolai Siebert, Silke Kietz, Penelope Brock, Alberto Garaventa, Dominique Valteau-Couanet, Evelyne Janzek, Norbert Hosten, Andreas Zinke, Winfried Barthlen, Emine Varol, Hans Loibner, Ruth Ladenstein, Holger N Lode
Immunotherapy with short term infusion (STI) of monoclonal anti-GD2 antibody (mAb) ch14.18 (4 × 25mg/m(2)/d; 8-20h) in combination with cytokines and 13-cis retinoic acid (RA) prolonged survival in high-risk neuroblastoma (NB) patients. Here, we investigated long-term infusion (LTI) of ch14.18 produced in Chinese hamster ovary cells (ch14.18/CHO; 10 × 10mg/m(2); 24h) in combination with subcutaneous (s.c.) interleukin-2 (IL-2) in a single center program and report clinical response, toxicity and survival...
November 9, 2017: MAbs
https://www.readbyqxmd.com/read/29113525/biological-mechanisms-underlying-the-clinical-effects-of-allergen-specific-immunotherapy-in-asthmatic-children
#8
Corrado Pelaia, Alessandro Vatrella, Nicola Lombardo, Rosa Terracciano, Paolo Navalesi, Rocco Savino, Girolamo Pelaia
Allergen-specific immunotherapy (AIT) is indicated for patients with allergic asthma and/or allergic rhinitis, and can be implemented by either subcutaneous injection (SCIT) or sublingual administration (SLIT). AIT reduces asthma symptoms, lowers the use of pharmacologic controller therapy, and decreases the need for rescue medications. SLIT appears to be safer than SCIT, but SCIT seems to be more efficacious and acts earlier in allergic asthmatic children. Areas covered: This review looks at the pathobiology of allergic asthma as well as the role of regulatory T and B cells in allergen tolerance...
November 8, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29109876/debut-of-gastroesophageal-reflux-concomitant-with-administration-of-sublingual-immunotherapy
#9
Jacob Juel
Gastroesophageal reflux disease (GORD) is an often debilitating condition characterised by retrograde flow of content from stomach into the oesophagus, where the low pH of the stomach acid irritates the mucosa of the oesophagus. The most dominant symptoms in GORD are pyrosis, regurgitation, and dysphagia. Sublingual immunotherapy (SLIT) was first described in 1986. Following this description, the use has greatly increased in the treatment of allergic rhinitis, as an alternative to subcutaneously administered immunotherapy...
2017: Case Reports in Gastrointestinal Medicine
https://www.readbyqxmd.com/read/29109772/the-anti-tumor-effects-of-m1-macrophage-loaded-poly-ethylene-glycol-and-gelatin-based-hydrogels-on-hepatocellular-carcinoma
#10
Alberto Daniel Guerra, Oscar W H Yeung, Xiang Qi, W John Kao, Kwan Man
Background and Aims: Recently we reported that direct injection of M1 macrophages significantly caused tumor regression in vivo. Despite the promising result, a major limitation in translating this approach is the induction of acute inflammatory response. To improve the strategy, a biocompatible scaffold for cell presentation and support is essential to control cell fate. Here, we aimed to elucidate the anti-tumor effects of a poly(ethylene glycol) diacrylate (PEGdA) and thiolated gelatin poly(ethylene glycol) (Gel-PEG-Cys) cross-linked hydrogels capsulated with M1 macrophages in both in vitro and in vivo disease models...
2017: Theranostics
https://www.readbyqxmd.com/read/29103453/clinical-applications-of-sublingual-immunotherapy
#11
REVIEW
Thomas S Edwards, Sarah K Wise
Sublingual immunotherapy (SLIT) is effective for the treatment of allergic rhinitis and allergic asthma in adults and children. In a limited number of studies, SLIT efficacy has been demonstrated for the treatment of food allergy. SLIT has a higher safety profile versus subcutaneous immunotherapy, although some systemic reactions have been reported. Appropriate patient selection, meticulous patient education, and routine follow-up are key for the safe and effective administration of SLIT. With organization and attention to detail, adding SLIT to one's practice can provide a highly valued patient service...
December 2017: Otolaryngologic Clinics of North America
https://www.readbyqxmd.com/read/29072624/an-archaeosome-adjuvanted-vaccine-and-checkpoint-inhibitor-therapy-combination-significantly-enhances-protection-from-murine-melanoma
#12
Felicity C Stark, Risini D Weeratna, Lise Deschatelets, Komal Gurnani, Renu Dudani, Michael J McCluskie, Lakshmi Krishnan
Archaeosomes constitute archaeal lipid vesicle vaccine adjuvants that evoke a strong CD8⁺ T cell response to antigenic cargo. Therapeutic treatment of murine B16-ovalbumin (B16-OVA) melanoma with archaeosome-OVA eliminates small subcutaneous solid tumors; however, they eventually resurge despite an increased frequency of circulating and tumor infiltrating OVA-CD8⁺ T cells. Herein, a number of different approaches were evaluated to improve responses, including dose number, interval, and the combination of vaccine with checkpoint inhibitors...
October 26, 2017: Vaccines
https://www.readbyqxmd.com/read/29066810/immunotherapy-with-subcutaneous-immunogenic-autologous-tumor-lysate-increases-murine-glioblastoma-survival
#13
Jochen Belmans, Matthias Van Woensel, Brecht Creyns, Joost Dejaegher, Dominique M Bullens, Stefaan W Van Gool
Immunotherapeutic strategies for glioblastoma, the most frequent malignant primary brain tumor, aim to improve its disastrous consequences. On top of the standard treatment, one strategy uses T cell activation by autologous dendritic cells (DC) ex vivo loaded with tumor lysate to attack remaining cancer cells. Wondering whether 'targeting' in vivo DCs could replace these ex vivo ones, immunogenic autologous tumor lysate was used to treat glioma-inoculated mice in the absence of ex vivo loaded DCs. Potential immune mechanisms were studied in two orthotopic, immunocompetent murine glioma models...
October 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29058249/a-2-year-step-down-withdrawal-from-inhaled-corticosteroids-in-asthmatic-children-receiving-immunotherapy
#14
Chun-Hui He, Xing Li, Jun-Hong Lin, Qiang Xiao, Jia-Lu Yu, Ying-Fen Liu, Wen-Hui Jiang, Chen Chen, Li Deng, Jie Zhou
BACKGROUND: Inhaled corticosteroids (ICSs) for treating asthma are controversial because of their negative effects on the growth of asthmatic children and without clearly defined withdrawal strategy. A 2-year ICS step-down and withdrawal strategy has been developed for asthmatic children receiving 3-year subcutaneous immunotherapy (SCIT). METHODS: Eleven children were included into the SCIT group and 13 children into the ICS group. ICSs were discontinued when children met the following criteria: requiring only 1 puffper day, with good control, for at least 6 months; having a forced expiratory volume in 1 second (FEV1)/forced vital capacity ≥80%; and SCIT discontinued for ≥24 months...
December 2017: World Journal of Pediatrics: WJP
https://www.readbyqxmd.com/read/29057538/enhanced-gastric-cancer-growth-potential-of-mesenchymal-stem-cells-derived-from-gastric-cancer-tissues-educated-by-cd4-t-cells
#15
Rongman Xu, Xiangdong Zhao, Yuanyuan Zhao, Bin Chen, Li Sun, Changgen Xu, Bo Shen, Mei Wang, Wenrong Xu, Wei Zhu
OBJECTIVES: Gastric cancer mesenchymal stem cells (GC-MSCs) can promote the development of tumour growth. The tumour-promoting role of tumour-associated MSCs and T cells has been demonstrated. T cells as the major immune cells may influence and induce a pro-tumour phenotype in MSCs. This study focused on whether CD4(+) T cells can affect GC-MSCs to promote gastric cancer growth. MATERIALS AND METHODS: CD4(+) T cells upregulation of programmed death ligand 1 (PD-L1) expression in GC-MSCs through the phosphorylated signal transducer and activator of transcription (p-STAT3) signalling pathway was confirmed by immunofluorescence, western blotting and RT-PCR...
October 22, 2017: Cell Proliferation
https://www.readbyqxmd.com/read/29046189/high-adherence-to-subcutaneous-immunotherapy-in-a-real-life-study-from-a-large-tertiary-medical-center
#16
Aslı Gelincik, Semra Demir, Müge Olgaç, Halim İşsever, Bayerma Khishigsuren, Ferhan Özşeker, Bahauddin Çolakoğlu, Suna Büyüköztürk
BACKGROUND: Studies on real-life adherence to subcutaneous allergen immunotherapy (SCIT) for respiratory allergy are scarce. The aim of this study was to evaluate adherence to SCIT. METHODS: The patients prescribed SCIT for allergic rhinitis and/or asthma in 2009-2011 were contacted in 2014 and asked whether they completed at least the 3 years of SCIT and/or whether they suspended the treatment for at least 2 months. The Total Symptom Score-6, visual analog scale (VAS), asthma control test (ACT), medication scores, quality of life (QoL) scores, and immunotherapy satisfaction scores with VAS obtained before the initiation of SCIT in the first year and at the end of SCIT were compared...
November 1, 2017: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29037263/long-term-effects-of-allergen-specific-subcutaneous-immunotherapy-for-house-dust-mite-induced-allergic-rhinitis
#17
E Sahin, D Dizdar, M E Dinc, A A Cirik
BACKGROUND: Allergic rhinitis is strongly associated with the presence of house dust mites. This study investigated the long-term effects of allergen-specific immunotherapy. Allergen-specific immunotherapy was applied over three years. The study was based on a 10-year follow up of patients with allergic rhinitis. METHODS: The study was conducted between 2001 and 2015. Skin prick test results and symptom scores were evaluated before (26 patients) and after 3 years (20 patients) of allergen-specific immunotherapy (using data from a previously published study), and 10 years after allergen-specific immunotherapy had ended (20 of 26 patients)...
October 17, 2017: Journal of Laryngology and Otology
https://www.readbyqxmd.com/read/29032329/successful-transdermal-allergen-delivery-and-allergen-specific-immunotherapy-using-biodegradable-microneedle-patches
#18
Ji Hye Kim, Jung U Shin, Seo Hyeong Kim, Ji Yeon Noh, Hye Ran Kim, Jungsoo Lee, Howard Chu, Kyoung Yong Jeong, Kyung Hee Park, Jung Dong Kim, Hong Kee Kim, Do Hyeon Jeong, Tai-Soon Yong, Jung-Won Park, Kwang Hoon Lee
Allergen-specific immunotherapy (SIT) is an effective treatment modality for allergic diseases such as atopic dermatitis (AD). However, frequent visits over a 3-year period as well as looming adverse events tend to discourage patient compliance. Therefore, a more convenient, effective, and safe method of SIT is needed. For several decades, use of microneedles has been promoted as an efficient and precise transdermal drug delivery method. In this study, we developed Dermatophagoides farinae (D. farinae) extract (DfE)-loaded microneedle patches, and evaluated their safety and efficacy as a novel SIT method...
October 4, 2017: Biomaterials
https://www.readbyqxmd.com/read/29021893/the-efficacy-of-oral-and-subcutaneous-antigen-specific-immunotherapy-in-murine-cow-s-milk-and-peanut-allergy-models
#19
Marlotte M Vonk, Laura Wagenaar, Raymond H H Pieters, Leon M J Knippels, Linette E M Willemsen, Joost J Smit, Betty C A M van Esch, Johan Garssen
BACKGROUND: Antigen-specific immunotherapy (AIT) is a promising therapeutic approach for both cow's milk allergy (CMA) and peanut allergy (PNA), but needs optimization in terms of efficacy and safety. AIM: Compare oral immunotherapy (OIT) and subcutaneous immunotherapy (SCIT) in murine models for CMA and PNA and determine the dose of allergen needed to effectively modify parameters of allergy. METHODS: Female C3H/HeOuJ mice were sensitized intragastrically (i...
2017: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/29016879/agonist-ox40-immunotherapy-improves-survival-in-glioma-bearing-mice-and-is-complementary-with-vaccination-with-irradiated-gm-csf-expressing-tumor-cells
#20
Nusrat Jahan, Hammad Talat, William T Curry
Background: Glioma immunotherapy is an active area of clinical investigation. Glioma-associated immunosuppression remains an obstacle to efficacious immunotherapy, and combination approaches are likely necessary for durable success. OX40 is a member of the tumor necrosis factor receptor superfamily that is upregulated on activated lymphocytes, ligation of which results in enhanced activity and may be active against cancer. We sought to confirm the efficacy of agonist anti-OX40 immunotherapy against glioma and hypothesized that it is complementary with irradiated whole tumor cell vaccination...
July 7, 2017: Neuro-oncology
keyword
keyword
54124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"